In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Clinical Trials Commercial

QUOTED. July 27, 2018. Opher Shapira.

  • News

Executive Summary

Israeli cancer diagnostics firm Nucleix is planning to scale up European commercial activities to expand the reach of its first product for bladder cancer, Bladder EpiCheck. See what Nucleix CEO Opher Shapira said about it here.

"The company is currently in advanced negotiations with additional leading distributors in various European countries to expand its commercial reach. We believe Bladder EpiCheck shows the best performance of bladder cancer recurrence detection compared to all other noninvasive solutions. In addition, the test is easy to adopt in any lab and is highly cost-effective." –Opher Shapira, CEO, Nucleix

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Clinical Trials Commercial
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

MT123038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By